Recent Updates
Recently added Catalysts
PFE Positive Sentiment

Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules

Tuesday, October 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Enodia Therapeutics has announced a research collaboration and license agreement with Pfizer to develop Sec61 inhibitors. This partnership aims to leverage Enodia's proprietary platform for discovering and advancing novel small-molecule therapeutics. The collaboration is expected to enhance the capabilities of both companies in targeted protein degradation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration with Pfizer enhances research capabilities.
  • Focus on innovative small-molecule therapies.
  • Potential for accelerated drug discovery.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+6%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
ibuzatrelvir
Phase 3 · COVID-19 Infection

Full Press Release Details

PARIS--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform. Enodia’s proprietary platform enables se

Frequently Asked Questions

What is the focus of the Enodia and Pfizer collaboration?

The collaboration focuses on discovering and developing Sec61 inhibitors.

What type of therapies is Enodia developing?

Enodia is developing novel small-molecule therapies for targeted protein degradation.

What is Enodia's proprietary platform used for?

It is used to accelerate the discovery of small-molecule therapeutics.

Who is Enodia Therapeutics collaborating with?

Enodia Therapeutics is collaborating with Pfizer Inc.

ShareAdd on Google
Tags: PFE Enodia Therapeutics Pfizer Sec61 inhibitors small-molecule therapies biotechnology
Last updated: Oct 13, 2026

Biotech snapshot

Cash runway
$11699M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ibuzatrelvirPhase 3
COVID-19 Infection →

Catalyst track record

+6%
best trade around PFE's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for PFE.

See every catalyst's timing & PoA →